-DOCSTART- -X- O
Enterovirus -X- _ B-Patient
71 -X- _ I-Patient
( -X- _ I-Patient
EV71 -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
a -X- _ O
group -X- _ O
of -X- _ O
viruses -X- _ O
that -X- _ O
belongs -X- _ O
to -X- _ O
the -X- _ O
Picornaviridae -X- _ O
family -X- _ O
, -X- _ O
which -X- _ O
also -X- _ O
includes -X- _ O
viruses -X- _ O
such -X- _ O
as -X- _ O
polioviruses. -X- _ O
EV71 -X- _ B-Patient
, -X- _ O
together -X- _ O
with -X- _ O
coxsackieviruses -X- _ O
, -X- _ O
is -X- _ O
widely -X- _ O
known -X- _ O
for -X- _ O
its -X- _ O
association -X- _ O
with -X- _ O
Hand -X- _ O
Foot -X- _ O
Mouth -X- _ O
Disease -X- _ O
( -X- _ O
HFMD -X- _ O
) -X- _ O
, -X- _ O
which -X- _ O
generally -X- _ O
affects -X- _ O
children -X- _ O
age -X- _ O
five -X- _ O
and -X- _ O
below. -X- _ O
Besides -X- _ O
HFMD -X- _ O
, -X- _ O
EV71 -X- _ B-Patient
can -X- _ O
also -X- _ O
trigger -X- _ O
more -X- _ O
severe -X- _ O
and -X- _ O
life-threatening -X- _ O
neurological -X- _ O
conditions -X- _ O
such -X- _ O
as -X- _ O
encephalitis. -X- _ O
Considering -X- _ O
the -X- _ O
lack -X- _ O
of -X- _ O
a -X- _ O
vaccine -X- _ O
and -X- _ O
antiviral -X- _ O
drug -X- _ O
against -X- _ O
EV71 -X- _ O
, -X- _ O
together -X- _ O
with -X- _ O
the -X- _ O
increasing -X- _ O
spread -X- _ O
of -X- _ O
these -X- _ O
viruses -X- _ O
, -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
such -X- _ O
drugs -X- _ O
and -X- _ O
vaccines -X- _ O
becomes -X- _ O
the -X- _ O
top -X- _ O
priority -X- _ O
in -X- _ O
protecting -X- _ O
our -X- _ O
younger -X- _ O
generations. -X- _ O
This -X- _ O
article -X- _ O
, -X- _ O
hence -X- _ O
, -X- _ O
reviews -X- _ O
some -X- _ O
of -X- _ O
the -X- _ O
recent -X- _ O
progress -X- _ O
in -X- _ O
the -X- _ O
formulations -X- _ O
of -X- _ O
anti-therapeutics -X- _ O
and -X- _ O
vaccine -X- _ O
generation -X- _ O
for -X- _ O
EV71 -X- _ B-Patient
, -X- _ O
covering -X- _ O
( -X- _ O
i -X- _ O
) -X- _ O
inactivated -X- _ B-Intervention
vaccines -X- _ I-Intervention
; -X- _ I-Intervention
( -X- _ I-Intervention
ii -X- _ I-Intervention
) -X- _ I-Intervention
baculovirus-expressed -X- _ I-Intervention
vaccines -X- _ I-Intervention
against -X- _ I-Intervention
EV71 -X- _ I-Intervention
; -X- _ I-Intervention
( -X- _ I-Intervention
iii -X- _ I-Intervention
) -X- _ I-Intervention
human -X- _ I-Intervention
intravenous -X- _ I-Intervention
immunoglobulin -X- _ I-Intervention
( -X- _ I-Intervention
IVIg -X- _ I-Intervention
) -X- _ I-Intervention
treatment -X- _ I-Intervention
; -X- _ I-Intervention
and -X- _ I-Intervention
( -X- _ I-Intervention
iv -X- _ I-Intervention
) -X- _ I-Intervention
the -X- _ I-Intervention
use -X- _ I-Intervention
of -X- _ I-Intervention
monoclonal -X- _ I-Intervention
antibody -X- _ I-Intervention
therapy -X- _ I-Intervention
as -X- _ O
a -X- _ O
prevention -X- _ O
and -X- _ O
treatment -X- _ O
for -X- _ O
EV71 -X- _ O
infections -X- _ O
. -X- _ O

